CERS2 and hepatocellular carcinoma: The median TTR was 28.9 (95% CI: 23.2–34.5) months for patients with HCC who had low expression of LASS2 and 45.9 (95% CI: 38.9–53.0) months for patients with HCC who had high expression of LASS2 (p = 0.0001, Fig. 2B).